INmune Bio Inc.https://investorshangout.com/INmune-Bio-Inc-INMB-93235/en-usFri, 04 Sep 2026 18:48:44 GMTCopyright InvestorsHangout.comznewcar1: INMB 26% v1,8M c14.08 f10,9M H14.74 looking strong aft hourshttps://investorshangout.com/post/view?id=5832817https://investorshangout.com/post/view?id=5832817Mon, 20 Jul 2020 22:21:52 GMTznewcar1: INMB 77% v44,7M c15.75 f10,8M gap up dip to 14 then to HOD@24.42 found S@15.55 tried to BO HOD yet fhttps://investorshangout.com/post/view?id=5826710https://investorshangout.com/post/view?id=5826710Wed, 15 Jul 2020 00:10:14 GMTznewcar1: INMB 26% v2,0M c8.85 f10,8M postMH22 nice double tomorrows talk https://investorshangout.com/post/view?id=5825320https://investorshangout.com/post/view?id=5825320Mon, 13 Jul 2020 22:32:58 GMTznewcar1: INMB 26% v727K c4.80 f10,7M H6.45 S4.54https://investorshangout.com/post/view?id=5700249https://investorshangout.com/post/view?id=5700249Wed, 11 Mar 2020 23:52:15 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Highlighted During Press Conferenchttps://investorshangout.com/post/view?id=5571689https://investorshangout.com/post/view?id=5571689Tue, 22 Oct 2019 20:34:35 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presentedhttps://investorshangout.com/post/view?id=5567831https://investorshangout.com/post/view?id=5567831Thu, 17 Oct 2019 19:50:53 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immunhttps://investorshangout.com/post/view?id=5559732https://investorshangout.com/post/view?id=5559732Tue, 08 Oct 2019 20:28:22 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Intervihttps://investorshangout.com/post/view?id=5547529https://investorshangout.com/post/view?id=5547529Tue, 24 Sep 2019 20:32:35 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present XPro1595 for Treating Neuroinflammhttps://investorshangout.com/post/view?id=5546511https://investorshangout.com/post/view?id=5546511Mon, 23 Sep 2019 21:19:26 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compoundhttps://investorshangout.com/post/view?id=5541563https://investorshangout.com/post/view?id=5541563Tue, 17 Sep 2019 20:04:53 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Coverihttps://investorshangout.com/post/view?id=5537712https://investorshangout.com/post/view?id=5537712Thu, 12 Sep 2019 21:31:12 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Resultshttps://investorshangout.com/post/view?id=5524183https://investorshangout.com/post/view?id=5524183Wed, 28 Aug 2019 21:18:20 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03 https://investorshangout.com/post/view?id=5519925https://investorshangout.com/post/view?id=5519925Fri, 23 Aug 2019 21:14:26 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategihttps://investorshangout.com/post/view?id=5513106https://investorshangout.com/post/view?id=5513106Fri, 16 Aug 2019 20:31:35 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides https://investorshangout.com/post/view?id=5508236https://investorshangout.com/post/view?id=5508236Mon, 12 Aug 2019 19:16:41 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Mehttps://investorshangout.com/post/view?id=5505406https://investorshangout.com/post/view?id=5505406Thu, 08 Aug 2019 19:38:13 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherhttps://investorshangout.com/post/view?id=5504325https://investorshangout.com/post/view?id=5504325Wed, 07 Aug 2019 20:58:45 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase https://investorshangout.com/post/view?id=5502117https://investorshangout.com/post/view?id=5502117Mon, 05 Aug 2019 19:56:58 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of Internationhttps://investorshangout.com/post/view?id=5500387https://investorshangout.com/post/view?id=5500387Fri, 02 Aug 2019 21:02:09 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Hehttps://investorshangout.com/post/view?id=5499177https://investorshangout.com/post/view?id=5499177Thu, 01 Aug 2019 21:01:53 GMTNetworkNewsWire: Research Highlights Virtues of INmune Bio Inc.’s (NASDAQ: INMB) Strategy in Fighting Cancer with https://investorshangout.com/post/view?id=5495743https://investorshangout.com/post/view?id=5495743Mon, 29 Jul 2019 19:51:42 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflahttps://investorshangout.com/post/view?id=5488062https://investorshangout.com/post/view?id=5488062Fri, 19 Jul 2019 21:59:07 GMTNetworkNewsWire: TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimerhttps://investorshangout.com/post/view?id=5485988https://investorshangout.com/post/view?id=5485988Wed, 17 Jul 2019 21:16:55 GMTNetworkNewsWire: Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NAhttps://investorshangout.com/post/view?id=5484875https://investorshangout.com/post/view?id=5484875Tue, 16 Jul 2019 20:42:08 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maximhttps://investorshangout.com/post/view?id=5476156https://investorshangout.com/post/view?id=5476156Wed, 03 Jul 2019 19:42:18 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treathttps://investorshangout.com/post/view?id=5466601https://investorshangout.com/post/view?id=5466601Thu, 20 Jun 2019 19:51:31 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems https://investorshangout.com/post/view?id=5459221https://investorshangout.com/post/view?id=5459221Tue, 11 Jun 2019 19:49:02 GMTNetworkNewsWire: NetworkNewsBreaks – Why INmune Bio Inc. (NASDAQ: INMB) Is ‘One to Watch’ INmune Bio (NASDAhttps://investorshangout.com/post/view?id=5459211https://investorshangout.com/post/view?id=5459211Tue, 11 Jun 2019 19:43:33 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro159https://investorshangout.com/post/view?id=5454745https://investorshangout.com/post/view?id=5454745Wed, 05 Jun 2019 19:56:08 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitatihttps://investorshangout.com/post/view?id=5452759https://investorshangout.com/post/view?id=5452759Mon, 03 Jun 2019 19:56:42 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cahttps://investorshangout.com/post/view?id=5449967https://investorshangout.com/post/view?id=5449967Thu, 30 May 2019 20:08:10 GMTNetworkNewsWire: INmune Bio Inc. (NASDAQ: INMB) is “One to Watch” - INmune Bio’s IPO closed February 1, 201https://investorshangout.com/post/view?id=5448912https://investorshangout.com/post/view?id=5448912Wed, 29 May 2019 20:36:33 GMTNetworkNewsWire: NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Ninth Annual LD Micro Invitatiohttps://investorshangout.com/post/view?id=5447896https://investorshangout.com/post/view?id=5447896Tue, 28 May 2019 20:35:01 GMT